Carbon Measurement Methods for Cleaning Validation: Comparing Direct Combustion with Rinse and Swab Sampling Methods. - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Carbon Measurement Methods for Cleaning Validation: Comparing Direct Combustion with Rinse and Swab Sampling Methods.
Cleaning validation provides assurance that the quantity of residual substances collected from equipment surfaces are within permissible limits, helping to ensure quality control and safety in pharmaceutical manufacturing facilities. Three different cleaning validation methods for measuring the carbon in residual samples of various pharmaceutical substances were compared.


Pharmaceutical Technology Europe
Volume 24, Issue 8


TOC–LCPH, Shimadzu
The challenges of conducting cleaning validation are documented in the literature. R. Baffi et al., for example, described the diverse analytical challenges arising in validating cleaning procedures for biopharmaceutical products produced by recombinant DNA, in which a broad range of potential residual cellular components and trace levels of detergents must be quantified (1). M.A. Strege et al. described the total organic carbon (TOC) analysis of swab samples for cleaning validation of bioprocess fermentation equipment and discussed accuracy, limits of detection, limit of quantitation, linearity and precision (2). K.M. Jenkins et al. compared the advantages and disadvantages of multiple methods for cleaning validation, including high-performance liquid chromatography (HPLC), thin-layer chromatography (TLC), spectrometry, TOC and conductivity (3). A.J. Holmes et al. described the TOC method for measuring residual aspirin on aluminum, stainless steel, painted carbon steel and Plexiglas (4). The latter two authors describe the swab challenge as noted in the FDA guide to inspections of cleaning surfaces.

For cleaning validation using a TOC analyser, the following types of sampling methods are available:

  • rinse sampling
  • swab sampling with aqueous extraction
  • swab sampling with direct combustion.

These methods were compared using a total organic carbon analyser (TOC-LCPH, Shimadzu) to measure residual pharmaceutical products and their constituent substances.

Preparation of residue samples


Table I: Substances used for residue measurements.
Residue samples were prepared by applying various types of pharmaceutical products and their constituents to stainless steel pots. Compounds with varying levels of water solubility (i.e., soluble, insoluble and very insoluble) were evaluated to determine how each method performed. The water-soluble substances were dissolved in water and the water-insoluble substances were dissolved in ethanol or acetone, as shown in Table I. Solution concentrations were adjusted to 2,000 mgC/L (i.e., carbon concentration of 2000 mg/L).

The carbon contents of tranexamic acid (C8H15NO2), anhydrous caffeine (C8H10N4O2), isopropylantipyrine (C14H18N2O), and nifedipine (C17H18N2O6) were estimated by molecular formula. Carbon contents of Gentashin ointment (aminoglycoside antibiotic) and Rinderon ointment (corticosteroid) were determined with the TOC analyser by adding samples of the ointments directly into a solid-sample combustion unit (SSM-5000A, Shimadzu) since molecular formula for these compounds are unknown.

Each residue sample consisted of a 5-cm2 area on the surface of a pot to which 100 µL of each solution was applied and dried. Thus, there were 200 µg carbon in the sample at each application site.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
22%
To all process for new products only
12%
To select process for new products only
22%
To select processes for both new and legacy products
22%
Do not use QbD
24%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search
Source: Pharmaceutical Technology Europe,
Click here